MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma

A major clinical challenge of diffuse large B-cell lymphoma (DLBCL) is that up to 40% of patients have refractory disease or relapse after initial response to therapy as a result of drug-specific molecular resistance. The purpose of the present study was to investigate microRNA (miRNA) involvement i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Due, Hanne, Schönherz, Anna Amanda, Ryø, Laura, Primo, Maria Nascimento, Jespersen, Ditte Starberg, Thomsen, Emil Aagaard, Roug, Anne Stidholt, Xiao, Min, Tan, Xiaohong, Pang, Yuyang, Young, Ken H., Bøgsted, Martin, Mikkelsen, Jacob Giehm, Dybkær, Karen
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2019
Soggetti:
Lymphoid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6457225/
https://ncbi.nlm.nih.gov/pubmed/30967394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018029660
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi